BIND Therapeutics (BIND) Misses Q4 EPS by 11c

BIND Therapeutics (NASDAQ: BIND) reported Q4 EPS of ($0.51), $0.11 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $3 million versus the consensus estimate of $6 million.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
• Jefferies on Yeti Holdings Inc. (YETI): 'Reiterate Buy on Today's Weakness'